维奈托克与伏立康唑联合使用后出现的突破性侵袭性真菌感染
Breakthrough Invasive Fungal Infection After Coadministration of Venetoclax and Voriconazole.
作者信息
Hall Victoria G, Tang Kenny, Kumar Deepali, Rotstein Coleman, Chow Signy, Chan Steven M, Husain Shahid, Hosseini-Moghaddam Seyed M
机构信息
Transplant-Oncology Infectious Diseases, University Health Network, Toronto, Ontario, Canada.
Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
出版信息
Open Forum Infect Dis. 2023 Mar 16;10(3):ofad134. doi: 10.1093/ofid/ofad134. eCollection 2023 Mar.
Abstract
Venetoclax requires a 75% dose reduction when coadministered with voriconazole. In a 10-year historical cohort of treatment with venetoclax, we did not observe a worse hematologic outcome in patients who received voriconazole prophylaxis versus those who did not. Subtherapeutic voriconazole levels and a triazole exposure history may contribute to breakthrough invasive fungal infection.
摘要
维奈克拉与伏立康唑合用时需要将剂量降低75%。在一个接受维奈克拉治疗的10年历史队列中，我们没有观察到接受伏立康唑预防的患者与未接受预防的患者相比血液学结果更差。伏立康唑水平低于治疗剂量以及三唑类药物暴露史可能导致侵袭性真菌感染的突破。
相似文献
1
Breakthrough Invasive Fungal Infection After Coadministration of Venetoclax and Voriconazole.维奈托克与伏立康唑联合使用后出现的突破性侵袭性真菌感染
Open Forum Infect Dis. 2023 Mar 16;10(3):ofad134. doi: 10.1093/ofid/ofad134. eCollection 2023 Mar.
2
Evaluating a voriconazole dose modification guideline to optimize dosing in patients with hematologic malignancies.评估伏立康唑剂量调整指南以优化血液系统恶性肿瘤患者的给药方案。
J Oncol Pharm Pract. 2019 Sep;25(6):1305-1311. doi: 10.1177/1078155218786028. Epub 2018 Jul 12.
3
Posaconazole versus voriconazole as antifungal prophylaxis during induction therapy for acute myelogenous leukemia or myelodysplastic syndrome.泊沙康唑与伏立康唑用于急性髓系白血病或骨髓增生异常综合征诱导治疗期间的抗真菌预防
J Oncol Pharm Pract. 2019 Mar;25(2):398-403. doi: 10.1177/1078155218806975. Epub 2018 Oct 14.
4
Comparing the safety and efficacy of voriconazole versus posaconazole in the prevention of invasive fungal infections in high-risk patients with hematological malignancies.比较伏立康唑与泊沙康唑预防血液恶性肿瘤高危患者侵袭性真菌感染的安全性和有效性。
Int J Antimicrob Agents. 2017 Sep;50(3):384-388. doi: 10.1016/j.ijantimicag.2017.03.021. Epub 2017 Jul 8.
5
Secondary antifungal prophylaxis in allogeneic hematopoietic stem cell transplant recipients with invasive fungal infection.异基因造血干细胞移植受者侵袭性真菌感染的二级抗真菌预防
J Infect Dev Ctries. 2018 Sep 30;12(9):799-805. doi: 10.3855/jidc.9961.
6
Treatment of invasive fungal infections in clinical practice: a multi-centre survey on customary dosing, treatment indications, efficacy and safety of voriconazole.临床实践中侵袭性真菌感染的治疗：关于伏立康唑常规剂量、治疗指征、疗效及安全性的多中心调查
Int J Hematol. 2008 Mar;87(2):126-131. doi: 10.1007/s12185-008-0045-z. Epub 2008 Feb 21.
7
Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study.伏立康唑用于异基因造血干细胞移植受者侵袭性真菌感染的二级预防：VOSIFI 研究结果。
Haematologica. 2010 Oct;95(10):1762-8. doi: 10.3324/haematol.2009.020073. Epub 2010 Jul 15.
8
[Breakthrough of invasive fungal disease with posaconazole as primary prophylaxis after induction chemotherapy for acute myeloid leukemia].[泊沙康唑作为急性髓系白血病诱导化疗后主要预防措施对侵袭性真菌病的突破]
Zhonghua Nei Ke Za Zhi. 2020 Mar 1;59(3):213-217. doi: 10.3760/cma.j.issn.0578-1426.2020.03.008.
9
Simultaneous quantification of venetoclax and voriconazole in human plasma by UHPLC-MS/MS and its application in acute myeloid leukemia patients.UHPLC-MS/MS 法同时测定人血浆中 venetoclax 和 voriconazole 的浓度及其在急性髓系白血病患者中的应用。
J Pharm Biomed Anal. 2023 Apr 1;227:115279. doi: 10.1016/j.jpba.2023.115279. Epub 2023 Feb 1.
10
Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy.在接受造血干细胞移植或强化化疗的血液系统恶性肿瘤患者中，使用伏立康唑后发生的突破性接合菌病。
Bone Marrow Transplant. 2007 Apr;39(7):425-9. doi: 10.1038/sj.bmt.1705614. Epub 2007 Feb 19.
引用本文的文献
1
Chinese population may require further venetoclax dose reduction beyond guidelines when combined with voriconazole: real-world evidence from China.在中国人群中，与伏立康唑联用时，维奈克拉可能需要在指南基础上进一步降低剂量：来自中国的真实世界证据。
Front Pharmacol. 2025 May 30;16:1539233. doi: 10.3389/fphar.2025.1539233. eCollection 2025.
2
The Burden of Invasive Fungal Disease Following Chimeric Antigen Receptor T-Cell Therapy and Strategies for Prevention.嵌合抗原受体T细胞疗法后侵袭性真菌病的负担及预防策略
Open Forum Infect Dis. 2024 Mar 13;11(6):ofae133. doi: 10.1093/ofid/ofae133. eCollection 2024 Jun.
3
The impact of gene polymorphism and hepatic insufficiency on voriconazole dose adjustment in invasive fungal infection individuals.基因多态性和肝功能不全对侵袭性真菌感染患者伏立康唑剂量调整的影响。
Front Genet. 2023 Aug 24;14:1242711. doi: 10.3389/fgene.2023.1242711. eCollection 2023.
本文引用的文献
1
Incidence of Invasive Fungal Infections in Patients With Previously Untreated Acute Myeloid Leukemia Receiving Venetoclax and Azacitidine.接受维奈克拉和阿扎胞苷治疗的既往未治疗的急性髓系白血病患者侵袭性真菌感染的发生率
Open Forum Infect Dis. 2022 Sep 24;9(10):ofac486. doi: 10.1093/ofid/ofac486. eCollection 2022 Oct.
2
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN.成人 AML 的诊断与治疗：ELN 专家组代表发布的 2022 年国际专家建议
Blood. 2022 Sep 22;140(12):1345-1377. doi: 10.1182/blood.2022016867.
3
Comparison of Mold Active Triazoles as Primary Antifungal Prophylaxis in Patients With Newly Diagnosed Acute Myeloid Leukemia in the Era of Molecularly Targeted Therapies.新型靶向治疗时代初诊急性髓系白血病患者中新型三氮唑类药物作为预防性抗真菌治疗的比较。
Clin Infect Dis. 2022 Oct 29;75(9):1503-1510. doi: 10.1093/cid/ciac230.
4
Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia.伴有 venetoclax 和唑类抗真菌药物的急性髓系白血病患者的细胞减少持续时间。
Cancer. 2021 Jul 15;127(14):2489-2499. doi: 10.1002/cncr.33508. Epub 2021 Apr 1.
5
Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium.侵袭性真菌病的共识定义修订与更新：来自欧洲癌症研究与治疗组织和真菌病研究组教育与研究联合会。
Clin Infect Dis. 2020 Sep 12;71(6):1367-1376. doi: 10.1093/cid/ciz1008.
6
How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia.我们如何将维奈托克与低甲基化剂联合用于治疗新诊断的急性髓系白血病患者。
Leukemia. 2019 Dec;33(12):2795-2804. doi: 10.1038/s41375-019-0612-8. Epub 2019 Oct 18.
7
Defining breakthrough invasive fungal infection-Position paper of the mycoses study group education and research consortium and the European Confederation of Medical Mycology.定义突破性侵袭性真菌感染——医学真菌学研究组教育和研究联盟及欧洲医学真菌学会联合会立场文件。
Mycoses. 2019 Sep;62(9):716-729. doi: 10.1111/myc.12960. Epub 2019 Jul 19.
8
Breakthrough Fungal Infections in Patients With Leukemia Receiving Isavuconazole.白血病患者接受伊曲康唑治疗后出现突破性真菌感染。
Clin Infect Dis. 2018 Oct 30;67(10):1610-1613. doi: 10.1093/cid/ciy406.
9
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.在未经治疗的老年急性髓系白血病患者中，venetoclax 联合地西他滨或阿扎胞苷的安全性和初步疗效：一项非随机、开放标签、1b 期研究。
Lancet Oncol. 2018 Feb;19(2):216-228. doi: 10.1016/S1470-2045(18)30010-X. Epub 2018 Jan 12.
10
Management of Venetoclax-Posaconazole Interaction in Acute Myeloid Leukemia Patients: Evaluation of Dose Adjustments.急性髓系白血病患者中维奈克拉与泊沙康唑相互作用的管理：剂量调整评估
Clin Ther. 2017 Feb;39(2):359-367. doi: 10.1016/j.clinthera.2017.01.003. Epub 2017 Feb 1.
Zotero 插件